Insider · CIK 0001579829
Troy A. Ignelzi
Files at HRMY (Harmony Biosciences Holdings, Inc.), CTNM (Contineum Therapeutics, Inc.), RAPP (Rapport Therapeutics, Inc.). First filing Mar 13, 2025, latest Mar 13, 2025.
Troy A. Ignelzi files SEC Form 4 as CFO and director at RAPP (Rapport Therapeutics, Inc.), and also at HRMY (Harmony Biosciences Holdings, Inc.), CTNM (Contineum Therapeutics, Inc.). Since Mar 13, 2025, Troy A. Ignelzi has reported 1 open-market buy worth $101k and 0 open-market sells worth $0, the latest filed on Mar 13, 2025.
A track record needs three past buys with six months of prices behind them; Troy A. Ignelzi has 0, so none is measured yet.
The newest scored trade: bought $101k of RAPP on Mar 12, 2025, filed Mar 13, 2025, scored 40 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RAPP: Rapport Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | RAPPbuy Rapport Therapeutics, Inc. | $101k 10,000 shares | - | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Apr 2, 2026 | HRMY Harmony Biosciences Holdings, Inc. | AGrant or award Stock Optionderivative | +17,710 | $0.00 | $0 | 17,710 | Apr 6, 2026 |
| Feb 2, 2026 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +148,000 | $0.00 | $0 | 148,000 | Feb 4, 2026 |
| Jun 26, 2025 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +14,750 | $0.00 | $0 | 14,750 | Jun 26, 2025 |
| Mar 12, 2025 | RAPP Rapport Therapeutics, Inc. | POpen-market purchase Common Stock | +9,900 | $10.10 | $100k | 9,900 | Mar 13, 2025 |
| Mar 13, 2025 | RAPP Rapport Therapeutics, Inc. | POpen-market purchase Common Stock | +100 | $9.98 | $998 | 10,000 | Mar 13, 2025 |
| Feb 3, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +142,000 | $0.00 | $0 | 142,000 | Feb 4, 2025 |
Questions about Troy A. Ignelzi
Answered from the filings on this page, as of the latest one.
Is Troy A. Ignelzi buying or selling?
Not in the last 12 months. Troy A. Ignelzi's latest open-market trade on SEC Form 4 was bought $101k of RAPP on Mar 12, 2025.
How did Troy A. Ignelzi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Troy A. Ignelzi has 0.
Where does Troy A. Ignelzi file Form 4?
Troy A. Ignelzi has filed Form 4 at RAPP (Rapport Therapeutics, Inc.) as Chief Financial Officer; HRMY (Harmony Biosciences Holdings, Inc.); CTNM (Contineum Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.